NCT00725686 - Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Age-Related Macular Degeneration

Interventions

DRUG

PF-04523655

This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months

Trial Locations (11)

10022

Pfizer Investigational Site, New York

21205

Pfizer Investigational Site, Baltimore

33136

Pfizer Investigational Site, Miami

44195

Pfizer Investigational Site, Cleveland

49100

Pfizer Investigational Site, Petah Tikva

64239

Pfizer Investigational Site, Tel Aviv

76100

Pfizer Investigational Site, Rehovot

90211

Pfizer Investigational Site, Beverly Hills

91105

Pfizer Investigational Site, Pasadena

94598

Pfizer Investigational Site, Walnut Creek

96701

Pfizer Investigational Site, ‘Aiea